Gilead Sciences (GILD) Aktsia Kursus
Gilead Sciences Kursus
Viimase 19 aasta jooksul kasvas Gilead Sciences käive 12,7 % aastas ja jõudis 29,44 B USD-ni. Kasum aktsia kohta kasvas 12,1 % aastas viimase 18 aasta jooksul. Gilead Sciences netomarginaal 28,9 % on tõusnud võrreldes 22,8 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 1,81 %. Väljamaksesuhe on umbes 47 % kasumist. Dividend kasvas 9,4 % aastas viimase 10 aasta jooksul. Gilead Sciences 12 kuu konsensuse hinnasiht on 155,00 USD, umbes alla kurssi 11,2 %. 36 analüütikust 30 soovitab osta — üldine konsensus on Osta.
Gilead Sciences aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Gilead Sciences ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Gilead Sciences aktsia kohta
Gilead Sciences Inc is a biopharmaceutical company with a diversified business model. Its primary focus is on the research, development, and commercialization of innovative medications to treat and prevent life-threatening diseases. Gilead operates in multiple therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, respiratory, cardiovascular, and viral infections. The company's business model revolves around discovering and designing new drugs, conducting clinical trials, obtaining regulatory approvals, manufacturing, marketing, and distribution of its pharmaceutical products. Through strategic collaborations and acquisitions, Gilead continuously expands its portfolio and aims to improve the quality of life for patients worldwide.
Gilead Sciences Inc is primarily active in the pharmaceutical industry.
The main competitors of Gilead Sciences Inc in the market include renowned companies like AbbVie, Bristol-Myers Squibb, and Merck & Co. These pharmaceutical giants operate in similar therapeutic areas and engage in the research, development, and commercialization of innovative medicines. At present, Gilead Sciences Inc faces competition in the fields of antiviral drugs, liver diseases, HIV/AIDS treatments, and oncology from these prominent industry players.
Gilead Sciences Inc, a leading biopharmaceutical company, was founded in 1987 by Dr. Michael L. Riordan in Foster City, California, USA. It specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Gilead has a rich history of pioneering breakthrough treatments for critical diseases such as HIV/AIDS, hepatitis, and other viral infections. With a mission to advance patient care globally, Gilead has expanded its portfolio through strategic acquisitions and collaborations, constantly striving to improve and save lives. Today, Gilead Sciences Inc remains committed to research, development, and manufacturing of transformative therapies across various therapeutic areas.
Gilead Sciences Inc has achieved several significant milestones throughout its history. It gained global recognition with the development of groundbreaking antiviral drugs such as Sovaldi and Harvoni, revolutionizing the treatment of hepatitis C. The company also made remarkable progress in the field of HIV, introducing a single-tablet regimen named Genvoya, providing convenient and effective therapy. Gilead Sciences Inc further expanded its therapeutic areas, bringing forth innovative treatments for life-threatening diseases like cancer and autoimmune disorders. Moreover, it received approval for its antiviral drug, remdesivir, as a treatment for COVID-19. These milestones solidify Gilead Sciences Inc's position as a leader in the pharmaceutical industry.
Gilead Sciences Inc is primarily present in various countries and regions worldwide. Some key locations where the company has a strong presence include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including countries like Japan, Australia, and China), and Latin America (including countries like Brazil and Mexico). With a global footprint, Gilead Sciences Inc operates in multiple markets, providing its innovative biopharmaceutical products and therapies to patients across different continents.
Gilead Sciences Inc represents a commitment to improving the lives of patients through innovative research and development in the fields of life sciences and biotechnology. Their corporate philosophy emphasizes a patient-centered approach, scientific integrity, and a drive to address unmet medical needs. Gilead Sciences Inc focuses on developing breakthrough therapies and treatments to combat diseases such as HIV/AIDS, viral hepatitis, and other challenging illnesses. They prioritize collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality healthcare solutions. With a strong emphasis on scientific excellence and a dedication to addressing global health challenges, Gilead Sciences Inc continues to make a significant impact in the industry.
Analüütikud määravad Gilead Sciences aktsiale keskmiseks hinnasihi 153,33 USD (mediaan: 155,00 USD), mis on −12,1 % viimase hinna suhtes. Konsensus põhineb 36 analüütiku hinnangul.
36 analüütikut hindavad praegu Gilead Sciences aktsiat: 30 soovitab osta, 6 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Gilead Sciences teenib tulu 30,78 B USD ja kasumit aktsia kohta −0,40 USD.
Praeguse kursiga kaubeldakse Gilead Sciences aktsiaga 155,37 EUR (174,48 USD) juures.
Gilead Sciences aktsia (GILD) on noteeritud 10 börsil, sh: NASDAQ (GILD), London (0QYQ.L), SIX (Zürich) (GILD.SW), XETRA (GIS.DE), Frankfurt (GIS.F), München (GIS.MU), Düsseldorf (GIS.DU), Hamburg (GIS.HM).
Gilead Sciences Inc is a biopharmaceutical company that develops innovative therapies for serious diseases such as HIV, hepatitis B and C, cancer, lung and liver diseases. The company is headquartered in Foster City, California and has been publicly traded since 1987. Gilead operates worldwide and has offices in more than 30 countries. The business model of Gilead Sciences is based on the development, manufacturing and marketing of innovative drugs. The company specializes in discovering chemicals that enable effective treatment of diseases. In recent years, Gilead Sciences has focused on the development of drugs for hepatitis C and HIV, which has contributed to significant revenue growth. Gilead Sciences' products are divided into three divisions: 1. Infectious Diseases: This division includes drugs for the treatment of HIV, hepatitis B and C, and other infectious diseases. The most well-known and successful drug is Viread, used for the treatment of HIV and hepatitis B. Another promising drug is Harvoni, a combination of two active ingredients used to treat hepatitis C. 2. Oncology: This division includes drugs for the treatment of various types of cancer, such as multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The most well-known drug is Revlimid, used for the treatment of multiple myeloma and other types of cancer. 3. Inflammatory and respiratory diseases: This division includes drugs for the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and emphysema. The most well-known drug is Remicade, used for the treatment of inflammatory bowel disease. In recent years, Gilead Sciences has established itself as a leading biopharmaceutical company through significant acquisitions and acquisitions. For example, in 2017, Kite Pharma, a company specializing in cancer immunotherapy, was acquired for $11.9 billion. This acquisition allowed Gilead Sciences to expand its portfolio of oncology drugs and strengthen its market position. Gilead Sciences' business model is based on a strong research and development department that continuously discovers and introduces new drugs to the market. Gilead Sciences has a broad pipeline of drugs in development to provide effective treatment for serious diseases to patients worldwide. The company works closely with regulatory authorities to expedite the approval of new drugs. Overall, Gilead Sciences Inc is an innovative and successful biopharmaceutical company specializing in the development and marketing of drugs for the treatment of serious diseases. The company has established itself as a leading provider in this field in recent years and will continue to play a crucial role in the development of new therapies in the future.
oodatav Gilead Sciences käive on 30,78 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Gilead Sciences kasum on −500,02 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Gilead Sciences jaoks on praegu −437,23. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Gilead Sciences aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Gilead Sciences jaoks on praegu 7,10. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Gilead Sciences aktsia jaoks.
Eulpooli kvaliteedinäitaja Gilead Sciences jaoks on 5/10.
Gilead Sciences ISIN on US3755581036. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Gilead Sciences WKN on 885823. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Gilead Sciences ticker on GILD. Ticker-sümbol kasutatakse Gilead Sciences aktsiate kauplemiseks börsil.
Gilead Sciences aktsia
Gilead Sciences konkurendid
Gilead Sciences Börsiticker
Gilead Sciences FIGI
Kõik teised näitajad ja analüüsid Gilead Sciences kohta sügavamalt
Meie Gilead Sciences-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Gilead Sciences. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: